{
    "Clinical Trial ID": "NCT00024102",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Standard Chemotherapy",
        "  Patient/Physician choice of:",
        "  CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 by IV days 1 and 8) + 5-FU (600 mg/m^2 by IV days 1 and 8) repeated every 28 days for 6 cycles OR",
        "  AC: Cyclophosphamide (600 mg/m^2 by IV on day 1)+ doxorubicin (60 mg/m^2 by IV on day 1) repeated every 21 days for 4 cycles",
        "INTERVENTION 2: ",
        "  Capecitabine",
        "  Capecitabine (2000 mg/m^2 in 2 doses days 1-14) repeated every 21 days for 6 cycles."
    ],
    "Eligibility": [
        "Patients with operable, histologically confirmed adenocarcinoma of the female breast.",
        "  TNM Stage per AJCC Cancer Staging Manual 6th edition:",
        "  T1-4 (Tumor size > 1 cm), N0, M0 or T1-4, N1-3, M0",
        "  Patients with bilateral, synchronous breast cancer are eligible as long as one primary tumor meets the criteria above.",
        "  Patients with HER2/neu positive, negative or unknown disease are eligible for this trial.",
        "  Patients whose tumors are HER2 positive by either immunohistochemistry 3+ staining or demonstrate gene amplification by FISH will be eligible to receive trastuzumab, as outlined in the protocol.",
        "  Age 65 years or older",
        "  Performance status 0-2 (Common Toxicity Criteria).",
        "  Prior treatment:",
        "  Surgical resection -",
        "  All tumor should be removed by either a modified radical mastectomy or a lumpectomy. Patients must be registered  84 days from mastectomy or within 84 days of axillary dissection if patient's most extensive breast surgery was a breast sparing procedure.",
        "  Node dissection: Axillary node dissection is not required. Management of the axilla is at the discretion of the treating physician. There is no restriction on eligibility based on the number of nodes removed.",
        "  Mastectomy: There should be no evidence of gross or microscopic invasive tumor at the surgical resection margins noted in the final surgery or pathology reports for patients who have had a modified radical mastectomy. Patients with close margins (tumor < 1 mm from margin) are eligible.",
        "  Segmental mastectomy (lumpectomy): Although clear margins are preferable, DCIS or LCIS at the surgical resection margin will not render a patient who has undergone a segmental mastectomy ineligible for this study. Invasive tumor at the final resection margin will render a patient ineligible.",
        "  No prior chemotherapy for this malignancy.",
        "  Patients with a history of hypersensitivity to 5-FU or known dihydropyrimidine dehydrogenase (DPD) deficiency are not eligible to participate.",
        "  Patients may receive up to four weeks of tamoxifen therapy for this malignancy and still be eligible for study entry. Patients who received tamoxifen or raloxifene for purposes of chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications (including previous breast cancer) are eligible. Tamoxifen or raloxifene therapy should be discontinued before the patient is enrolled on this study.",
        "  Required Initial Laboratory Data:",
        "  Granulocytes > 1,500/\u00b5l",
        "  Platelet count 100,000/\u00b5l",
        "  Calculated Creatinine Clearance > 30 mL/min",
        "  Total bilirubin  ULN"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Relapse-free Survival Rates at 2.4 Years",
        "  Percentage of participants who were alive and relapse-free at time of analysis were counted as \"Alive without relapse\" at 2.4 years. Participants who had a first local recurrence, first distant metastasis or death from any cause were counted as \"relapse, first occurrence\". These rates were estimated using the Kaplan Meier method",
        "  Time frame: randomization until date of first event, or date last known to be event free if no event was reported (up to 5 years)",
        "Results 1: ",
        "  Arm/Group Title: Standard Chemotherapy",
        "  Arm/Group Description: Patient/Physician choice of:",
        "  CMF: cyclophosphamide (100 mg/m^2 orally days 1-14)+ MTX (40 mg/m^2 by IV days 1 and 8) + 5-FU (600 mg/m^2 by IV days 1 and 8) repeated every 28 days for 6 cycles OR",
        "  AC: Cyclophosphamide (600 mg/m^2 by IV on day 1)+ doxorubicin (60 mg/m^2 by IV on day 1) repeated every 21 days for 4 cycles",
        "  Overall Number of Participants Analyzed: 326",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  Relapse, first occurrence: 11",
        "  Alive without relapse: 89",
        "Results 2: ",
        "  Arm/Group Title: Capecitabine",
        "  Arm/Group Description: Capecitabine (2000 mg/m^2 in 2 doses days 1-14) repeated every 21 days for 6 cycles.",
        "  Overall Number of Participants Analyzed: 307",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  Relapse, first occurrence: 20",
        "  Alive without relapse: 80"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 15/131 (11.45%)",
        "  Disseminated intravascular coagulation 1/131 (0.76%)",
        "  Febrile neutropenia 5/131 (3.82%)",
        "  Hemoglobin decreased 7/131 (5.34%)",
        "  Lymphatics 1/131 (0.76%)",
        "  Transfusion: pRBCs 0/131 (0.00%)",
        "  Arrhythmia supraventricular 0/131 (0.00%)",
        "  Cardiac disorder 1/131 (0.76%)",
        "  Edema 0/131 (0.00%)",
        "  Left ventricular failure 0/131 (0.00%)",
        "  Myocardial ischemia 1/131 (0.76%)",
        "Adverse Events 2:",
        "  Total: 17/181 (9.39%)",
        "  Disseminated intravascular coagulation 0/181 (0.00%)",
        "  Febrile neutropenia 1/181 (0.55%)",
        "  Hemoglobin decreased 13/181 (7.18%)",
        "  Lymphatics 0/181 (0.00%)",
        "  Transfusion: pRBCs 1/181 (0.55%)",
        "  Arrhythmia supraventricular 1/181 (0.55%)",
        "  Cardiac disorder 0/181 (0.00%)",
        "  Edema 0/181 (0.00%)",
        "  Left ventricular failure 1/181 (0.55%)",
        "  Myocardial ischemia 0/181 (0.00%)"
    ]
}